Deep learning for low-data drug discovery: Hurdles and opportunities

Area of Science:

• Computational chemistry and cheminformatics
• Artificial intelligence in medicine
• Drug discovery and development

Background:

• Deep learning (DL) is increasingly vital in drug discovery, aiding tasks like de novo molecular design, protein structure prediction, and synthesis planning.
• A significant challenge for DL in drug discovery is the prevalence of small data regimes, where data-hungry algorithms may underperform.
• Addressing these low-data scenarios is crucial for realizing the full potential of DL in pharmaceutical research.

Purpose of the Study:

• To provide an overview of recent advancements in low-data learning approaches for drug discovery.
• To analyze the specific hurdles and advantages associated with these emerging methodologies.
• To forecast future research directions in the application of low-data learning within drug discovery.

Main Methods:

• Review of recent literature on low-data learning techniques applied to drug discovery tasks.
• Analysis of the performance, limitations, and benefits of various low-data learning strategies.
• Synthesis of findings to identify trends and predict future research avenues.

Main Results:

• Identification of key low-data learning approaches currently being explored in drug discovery.
• Evaluation of the practical challenges, such as data scarcity and model generalizability, encountered in these methods.
• Discussion of the advantages, including enhanced efficiency and novel insights, offered by successful low-data learning applications.

Conclusions:

• Low-data learning is a critical area for advancing deep learning applications in drug discovery.
• Overcoming data limitations is essential for unlocking the full potential of AI in pharmaceutical research.
• Future research should focus on developing innovative low-data learning techniques to accelerate drug discovery pipelines.